Is Amgen's Dividend Safe?
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares.
Big drug companies such as Amgen, AbbVie , and Johnson & Johnson offer investors predictable dividend-friendly revenue regardless of the economy's whims and whispers. But investors are correct to wonder whether Amgen's dividend can be sustained in light of billions in at-risk revenue tied to the future patent expiration of top-selling drugs.
In the following slideshow you'll see whether I think Amgen's dividend is safe and gain insight into how Amgen's dividend payout matches up with industry peers AbbVie and Johnson & Johnson.
Top dividend stocks for the next decade -- is Amgen one?
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
The article Is Amgen's Dividend Safe? originally appeared on Fool.com.Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.